Although the American public opposition to the new president of Trump high, but in the presidential election, the price of biomedical stocks is ushered in a large rebound in the year downturn trend. Recently, the GEN website counted 10 biomedical technology companies with the biggest winners on Wall Street in 2016. The highest return on investment in the secondary market was Axim Biotechnologies, and the stock price has increased 28 times in a year. a list of the top 10 best stock performers of 2016 As shown in the above chart, this list includes basic information on outstanding stocks: company name, trading market, stock code, closing price on December 30, 2016 and December 30, 2015, stock gains, etc. #10. Argos Therapeutics NASDAQ: ARGS December 30, 2016: $4.90 December 30, 2015: $2.44 % Change: 100.8% Argos Therapeutics was founded in 1997 by Nobel Prize winner Ralph Steinman, specializing in the development and commercialization of personalized immunotherapy for cancer and HIV-infected diseases. It was launched on the NASDAQ in February 2014. Argos' proprietary Arcelis technology platform is a therapeutic platform for creating fully personalized immunotherapy based on patient dendritic cells and tumor samples. AGS-003 is one of the products developed on this platform, and is a global leader in metastatic renal cell carcinoma. The tumor cell immunotherapy is currently in the phase III phase of clinical trials for the treatment of metastatic renal cancer. To this end, the expectation of AGS-003 caused the company's stock to peak at $12.44 on April 18, 2016, but the following day, the company announced that 13% of layoffs had a total of 18 layoffs, including the departure of company COO Fred Miesowicz. Then, the company's stock fluctuated at $5. The company's top data from ADAPT will be reported in the first half of 2017. #9. Merus NASDAQ: MRUS December 30, 2016: $21.11 December 30, 2015: N/A (Stock began trading on May 19, 2016, following an initial public offering at $10 a share) % Change: 111.1% A year after the IPO, Merus is a highly successful company that develops tumor immunotherapy for innovative humanized bispecific antibodies. In December last year, when the company signed an exclusive partnership with Incyte for 11 bispecific antibody development projects (including two preclinical research projects for tumor immunotherapy), it received up to $120 million in advance payments and 8,000 Ten thousand dollar equity investment. On the 8th day after the news was announced (December 29), the company's share price jumped to a record high of $21.38. Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com
